Atossa Genetics Inc. (ATOS) financial statements (2021 and earlier)

Company profile

Business Address 107 SPRING STREET
SEATTLE, WA 98104
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments401310734
Cash and cash equivalents401310734
Restricted cash and investments00000 
Receivables   0  
Prepaid expense211000
Other current assets1000 0
Other undisclosed current assets111  0
Total current assets:431412834
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment000000
Intangible assets, net (including goodwill)   012
Intangible assets, net (excluding goodwill)   012
Other noncurrent assets000000
Other undisclosed noncurrent assets000   
Total noncurrent assets:000012
TOTAL ASSETS:431412846
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities311112
Accounts payable200001
Accrued liabilities000000
Employee-related liabilities111111
Debt 0    
Deferred compensation liability  1   
Other liabilities000000
Other undisclosed current liabilities13     
Total current liabilities:1613113
Noncurrent Liabilities
Long-term debt and lease obligation 0    
Operating lease, liability 0
Total noncurrent liabilities: 0    
Total liabilities:1613113
Stockholders' equity
Stockholders' equity attributable to parent, including:27139734
Preferred stock000   
Common stock921000
Additional paid in capital13010685726055
Accumulated deficit(112)(94)(77)(65)(57)(51)
Other undisclosed stockholders' equity attributable to parent1     
Total stockholders' equity:27139734
TOTAL LIABILITIES AND EQUITY:431412846

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues
(Revenue, Net)
     0
Cost of revenue
(Cost of Goods and Services Sold)
     (0)
Gross profit:     (0)
Operating expenses(15)(17)(11)(8)(8)(13)
Operating loss:(15)(17)(11)(8)(8)(13)
Nonoperating income000020
Investment income, nonoperating   (0)(0) 
Other nonoperating income000   
Interest and debt expense   (0)(0)(0)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes   (0) 0
Loss from continuing operations before equity method investments, income taxes:(15)(17)(11)(8)(6)(13)
Other undisclosed income (loss) from continuing operations before income taxes(3)   0 
Loss before gain (loss) on sale of properties:(18)(17)(11)(8)(6)(13)
Other undisclosed net loss     (3)
Net loss attributable to parent:(18)(17)(11)(8)(6)(16)
Preferred stock dividends and other adjustments   (3)  
Other undisclosed net loss available to common stockholders, basic(5) (11)   
Net loss available to common stockholders, diluted:(22)(17)(23)(11)(6)(16)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(18)(17)(11)(8)(6)(16)
Comprehensive loss, net of tax, attributable to parent:(18)(17)(11)(8)(6)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: